Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials
- PMID: 16444865
- DOI: 10.1177/1358836X0501000104
Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials
Abstract
Evidence has accumulated that asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide (NO) synthase. ADMA inhibits vascular NO production at concentrations found in pathophysiological conditions; it also causes local vasoconstriction when infused intra-arterially. ADMA is increased in the plasma of humans with hypercholesterolemia, atherosclerosis, hypertension, chronic renal failure, chronic heart failure, and other clinical conditions. Increased ADMA levels are associated with reduced NO synthesis as assessed by impaired endothelium-dependent vasodilation or reduced NO metabolite levels. In several prospective and cross-sectional studies, ADMA has evolved as a marker of cardiovascular risk. Moreover, prospective clinical studies have suggested that it may play a role as a novel cardiovascular risk factor. Zoccali and coworkers were the first to show that elevated ADMA is associated with a three-fold increased risk of future severe cardiovascular events and mortality in patients undergoing hemodialysis. Valkonen and coworkers demonstrated in a nested case-control study that elevated ADMA was associated with a four-fold increased risk for acute coronary events in clinically healthy, nonsmoking men. In patients with stable angina pectoris, preinterventional ADMA indicates the risk of developing restenosis or severe clinical events after coronary intervention. Furthermore, in humans with no underlying cardiovascular disease who are undergoing intensive care unit treatment, ADMA is a marker of the mortality risk. A number of additional prospective clinical trials are currently under way in diverse patient populations, among them individuals with congestive heart failure, cardiac transplantation patients, and patients with pulmonary hypertension. In summary, an increasing number of prospective clinical trials have shown that the association between elevated ADMA levels and major cardiovascular events and total mortality is robust and extends to diverse patient populations. However, we need to define more clearly in the future who will profit from ADMA determination, in order to use this novel risk marker as a more specific diagnostic tool.
Similar articles
-
Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.J Nutr. 2004 Oct;134(10 Suppl):2842S-2847S; discussion 2853S. doi: 10.1093/jn/134.10.2842S. J Nutr. 2004. PMID: 15465797 Review.
-
Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).Vasc Med. 2005 Jul;10 Suppl 1:S49-57. doi: 10.1191/1358863x05vm605oa. Vasc Med. 2005. PMID: 16444869 Review.
-
Association of asymmetric dimethylarginine and endothelial dysfunction.Clin Chem Lab Med. 2003 Nov;41(11):1467-72. doi: 10.1515/CCLM.2003.225. Clin Chem Lab Med. 2003. PMID: 14656027 Review.
-
Plasma concentration of asymmetric dimethylarginine and the risk of coronary heart disease: rationale and design of the multicenter CARDIAC study.Atheroscler Suppl. 2003 Dec;4(4):29-32. doi: 10.1016/s1567-5688(03)00031-x. Atheroscler Suppl. 2003. PMID: 14664900 Review.
-
The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.Cardiovasc Res. 2003 Oct 1;59(4):824-33. doi: 10.1016/s0008-6363(03)00500-5. Cardiovasc Res. 2003. PMID: 14553822 Review.
Cited by
-
Metabolomics reveals that tumor xenografts induce liver dysfunction.Mol Cell Proteomics. 2013 Aug;12(8):2126-35. doi: 10.1074/mcp.M113.028324. Epub 2013 May 1. Mol Cell Proteomics. 2013. PMID: 23637421 Free PMC article.
-
Asymmetric Dimethylarginine as a Potential Mediator in the Association between Periodontitis and Cardiovascular Disease: A Systematic Review of Current Evidence.Dent J (Basel). 2024 Sep 21;12(9):297. doi: 10.3390/dj12090297. Dent J (Basel). 2024. PMID: 39329863 Free PMC article. Review.
-
Asymmetric dimethylarginine levels are associated with augmentation index across naïve untreated patients with different hypertension phenotypes.J Clin Hypertens (Greenwich). 2018 Apr;20(4):680-685. doi: 10.1111/jch.13237. Epub 2018 Feb 15. J Clin Hypertens (Greenwich). 2018. PMID: 29447435 Free PMC article.
-
Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tables.Hypertension. 2012 Feb;59(2):375-81. doi: 10.1161/HYPERTENSIONAHA.111.187310. Epub 2012 Jan 3. Hypertension. 2012. PMID: 22215715 Free PMC article. Review.
-
Asymmetric dimethylarginine induces maladaptive function of the blood-brain barrier.Front Cell Dev Biol. 2024 Oct 9;12:1476386. doi: 10.3389/fcell.2024.1476386. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 39445335 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources